← Browse by Condition
Medical Condition

classical hodgkin lymphoma

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2

Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas β€” each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.

Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.

Frequently Asked Questions — classical hodgkin lymphoma Clinical Trials

How many clinical trials are currently recruiting for classical hodgkin lymphoma?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for classical hodgkin lymphoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for classical hodgkin lymphoma?
classical hodgkin lymphoma research spans Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a classical hodgkin lymphoma clinical trial?
Eligibility criteria for classical hodgkin lymphoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Top Sponsors
Fondazione Italiana Linfomi - ETS 1 trial
Assistance Publique - Hôpitaux de Paris 1 trial
University Health Network, Toronto 1 trial

Recruiting Clinical Trials

NCT05934084
Recruiting
Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors
Enrollment
552 pts
Location
Italy
Sponsor
Fondazione Italiana Linfomi - ...
View Trial →
NCT07356882
Recruiting
European Project for ctDNA Detection as a Biomarker for Non-invasive Therapy Monitoring in Paediatric Classical Hodgkin Lymphoma
Enrollment
400 pts
Location
France
Sponsor
Assistance Publique - Hôpitaux...
View Trial →
NCT04510636 Phase 2
Recruiting
Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma
Enrollment
40 pts
Location
Canada
Sponsor
University Health Network, Tor...
View Trial →

Related Conditions

diffuse large b cell lymphoma dlbcl (1) primary mediastinal large b cell lymphoma pmbcl (1) relapsed cancer (1) refractory cancer (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology